BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Subscribe To Our Newsletter & Stay Updated
